Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice-Reference-Cited by-同舟云学术

Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice

Published:2022-05 Issue: Volume:167 Page:87-97
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Steeghs Elisabeth M.P.^ORCID,Groen Harry J.M.,Schuuring Ed,Aarts Mieke J.,Damhuis Ronald A.M.,Voorham Quirinus J.M.,Ligtenberg Marjolijn J.L.,Grünberg Katrien

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference65 articles.

1. Final overall survival analysis from a study comparing first-line Crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer;Solomon;J. Clin. Oncol.,2018

2. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC;Ramalingam;N. Engl. J. Med.,2020

3. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer;Lin;Lung Cancer,2019

4. Understanding and targeting resistance mechanisms in NSCLC;Rotow;Nat. Rev. Cancer,2017

5. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc. Natl. Acad. Sci. U. S. A.,2004

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and treatment of human epidermal growth factor receptor 2-altered non-small cell lung cancer: a retrospective analysis and systematic literature review;ecancermedicalscience;2024-08-01

2. Prediction of Epidermal Growth Factor Receptor Mutation Subtypes in Non–Small Cell Lung Cancer From Hematoxylin and Eosin–Stained Slides Using Deep Learning;Laboratory Investigation;2024-08

3. Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands;European Journal of Cancer;2024-07

4. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries;The Lancet Regional Health - Europe;2024-03

5. Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy;PharmacoEconomics;2024-01-09